WellGen and HMGene forge obesity pact

HMGene will screen WellGen’s proprietary bioactive compounds against HMGene’s proprietary panel of genes involved in adipocyte development, the body’s natural mechanism for making fat cells. The screening process will identify new, natural bioactive compounds that will be targeted to weight loss and the control of obesity. Any resulting products will be commercialized by WellGen.

David Evans, WellGen’s CEO, said, “We’re very pleased to have HMGene as a partner. The combination of our patented screening technology with HMGene’s anti-obesity technology enables us to identify and develop a new generation of bioactive compounds that target obesity.”

Dr Kiran Chada, HMGene’s president and a professor of biochemistry at the University of Medicine and Dentistry of New Jersey, said, “Our relationship with WellGen provides us with an excellent opportunity to pursue commercial applications of our many years of research on the genetics of adipocyte development.”